MARKET

MDXG

MDXG

Mimedx Group Inc
NASDAQ
3.270
+0.020
+0.62%
After Hours: 3.270 0 0.00% 16:01 12/01 EST
OPEN
3.260
PREV CLOSE
3.250
HIGH
3.350
LOW
3.199
VOLUME
484.54K
TURNOVER
0
52 WEEK HIGH
7.64
52 WEEK LOW
2.590
MARKET CAP
371.69M
P/E (TTM)
-10.8171
1D
5D
1M
3M
1Y
5Y
MDXG: KOA Trial Launch Around the Corner
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT 3Q:22 Financial and Operational Results After market close on November 2, 2022, MiMedx Group, Inc. (NASDAQ:MDXG) filed its Form 10-Q with the SEC and issued a press release summarizin...
Zacks Small Cap Research · 11/03 10:32
BRIEF-Mimedx Announces Third Quarter 2022 Results
Reuters · 11/02 21:42
MiMedx Group GAAP EPS of -$0.09 in-line, revenue of $67.69M beats by $0.96M
Seekingalpha · 11/02 20:51
MiMedx Group Q3 EPS $(0.09) Misses $(0.08) Estimate, Sales $67.69M Beat $66.73M Estimate
Benzinga · 11/02 20:49
-- GUIDANCE: (MDXG) MIMEDX GROUP Sees Q4 Revenue Range $67.7M
-- GUIDANCE: (MDXG) MIMEDX GROUP Sees Q4 Revenue Range $67.7M
MT Newswires · 11/02 16:40
MiMedx Group Q3 2022 Earnings Preview
Seekingalpha · 11/01 21:35
MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2
MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the third quarter ended ...
GlobeNewswire · 10/19 12:00
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades
Benzinga · 10/13 14:05
More
About MDXG
MiMedx Group, Inc. is a transformational placental biologics company, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.